No Data
No Data
On May 31, A50ETF Huabao (159596) fell slightly by 0.1% with a turnover of 122 million yuan. Component stocks had mixed ups and downs; BYD rose 0.51%, CITIC Securities rose 0.32%; Zijin Mining fell 1.3%; Hengrui Pharmaceutical fell 1.21%. In terms of capi
On May 31, A50ETF Huabao (159596) fell slightly by 0.1% with a turnover of 122 million yuan. Component stocks had mixed ups and downs; BYD rose 0.51%, CITIC Securities rose 0.32%; Zijin Mining fell 1.3%; Hengrui Pharmaceutical fell 1.21%. In terms of capital flow, we have received a cumulative net inflow of over 200 million yuan in net capital inflows for 5 consecutive trading days! Recently, many foreign investors have boosted Chinese assets, and in particular, the target prices of some leading companies have been raised several times. Wang Zonghao, head of stock strategy research at UBS China, said that the current macroeconomic environment of the A-share market is close to the situation in 2015 and 2016, and the fundamentals of listed companies are better than 20
Hengrui Pharmaceutical (600276.SH): Subsidiary SHR-9539 Injection Obtains Drug Clinical Trial Approval Notice
Gelonghui, May 30丨Hengrui Pharmaceutical (600276.SH) announced that recently, the company's subsidiaries Shanghai Hengrui Pharmaceutical Co., Ltd. and Suzhou Shengdia Biomedical Co., Ltd. received approval from the State Drug Administration to issue a “Drug Clinical Trial Approval Notice” for SHR-9539 injections and will conduct clinical trials in the near future. SHR-9539 injection is a class 1 therapeutic biological product. By inducing and activating T cells, it exerts a targeted effect on killing multiple myeloma cells. Currently, no similar drugs have been approved for marketing in China. Up to now, SHR-9539 injection-related projects have been accumulated
Hengrui Pharmaceutical (600276): Once again successfully transformed, innovative drugs have become a new engine of growth, waiting to set sail
Fundamentals 1.1 Performance resumed growth trend, stock price trend and index converged 1.2 Financial health, profit margin continued to rise 1.3 The company's various business segments focused on popular and high-incidence areas, breaking through 1.4. The business model is average.
Hengrui Pharmaceuticals Gets Nod to Trial Vitiligo Drug
Jiangsu Hengrui Pharmaceuticals (SHA:600276) will conduct clinical trials on the SHR0302 alkaline gel as a treatment for vitiligo after obtaining the approval of Chinese drug regulator National Medica
Hengrui Pharmaceutical (600276.SH): SHR0302 alkali gel obtained drug clinical trial approval notice
Gelonghui May 29丨Hengrui Pharmaceutical (600276.SH) announced that it has received approval from the State Drug Administration to issue a “Pharmaceutical Clinical Trial Approval Notice” for SHR0302 alkali gel, and will conduct clinical trials in the near future. SHR0302 alkali gel is a topical, highly selective JAK1 inhibitor. It can exert anti-inflammatory and immune-suppressing biological effects by improving local exposure and better inhibiting JAK1 signaling.
Express News | Hengrui Pharmaceutical: The subsidiary HRS9531 tablets were approved for clinical trials
No Data